On September 9, 2011, an Advisory Committee of the FDA studying drug safety will meet to conduct a review of bisphosphonates. These drugs include Fosamax, which was approved in 1995 and prescribed for osteoporosis and Pagets disease of the bone. Some doctors have prescribed it for osteopenia. Studies have linked Fosamax with osteonecrosis of the jaw (ONJ) and femur (thigh bone) fractures. The FDA is considering drug holidays because of the risks of long-term use. Merck sells Fosamax and it will make a presentation to the Advisory Committee. Partner, Jim Pettit, is handling the firms Fosamax cases, and is filing them in Atlantic City, New Jersey. Mass Tort Judge Carol Higbee is managing all the Fosamax cases in the state.